Stanley A. Roberts

Dr. Roberts is Astrocyte Pharmaceuticals’ Head of Non-Clinical Safety Assessment, and he has over 30 years of experience in scientific and management positions in large (Sandoz, Abbott & Pfizer) and small (CovX) pharmaceutical companies. His executive management duties have included being the Global Director for Preclinical ADME/PK (Abbott) and VP of Preclinical Drug Development (CovX). Dr. Roberts has also held a variety of scientific and leadership positions in toxicology organizations. Dr. Roberts has planned/conducted/interpreted/reported all types of drug development plans and studies for toxicology and ADME/PK. Accomplishments include authoring over 400 internal company final reports, major contributions to numerous successful regulatory documents/strategies/submissions (white papers, IND, NDA, and BLA). Dr. Roberts has also conducted problem-solving research to evaluate the human relevance of animal toxicities as well as improving the quality of new drug candidate ADME/PK characteristics. Dr. Roberts has wide and deep experience in numerous disease targets including neuroscience and pain diseases using small molecules, peptides, biotherapeutics.

Dr. Roberts is experienced with in/out-licensing activities, managing and representing multidisciplinary teams, and has presented to the FDA on numerous occasions. He has extensive experience in numerous committees and special projects for PhRMA and BIO. Dr. Roberts has a BS (Animal Science), MS, and Ph.D. (Pharmacology & Toxicology) from Purdue University and a post-doctoral fellowship in Molecular Toxicology (Medical University of South Carolina).